Drug:
Reaction: DERMATITIS ATOPIC
20260101 - 20261231
No. 2301 - 2400
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 2301 | 26707866 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2302 | 26707930 |
US |
51 | 2 |
Gait disturbance, Stress, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2303 | 26707934 |
US |
29 | 2 |
Dermatitis atopic, Neurodermatitis, Menstrual disorder, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2304 | 26707940 |
US |
33 | 2 |
Dermatitis atopic, Erythema, Rash, |
||||
DUPILUMAB, |
||||
| 2305 | 26707965 |
US |
51 | 1 |
Dermatitis atopic, Skin exfoliation, |
||||
DUPILUMAB, |
||||
| 2306 | 26707982 |
US |
66 | 1 |
Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2307 | 26708051 |
US |
67 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2308 | 26708241 |
US |
3 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2309 | 26708255 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2310 | 26708260 |
US |
75 | 1 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 2311 | 26708262 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2312 | 26708276 |
GB |
||
Angioedema, Urticaria, Cellulitis, Dermatitis atopic, Urinary tract infection, Peripheral swelling, Condition aggravated, Swelling face, Blood pressure increased, Heart rate increased, Dyspnoea, Therapeutic product effect incomplete, |
||||
NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, |
||||
| 2313 | 26708312 |
US |
48 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2314 | 26708347 |
US |
63 | 2 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2315 | 26708352 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2316 | 26708361 |
US |
16 | 2 |
Dermatitis atopic, Therapeutic response decreased, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2317 | 26708713 |
US |
64 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2318 | 26708721 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2319 | 26708930 |
US |
53 | 2 |
Dermatitis atopic, Eczema, Rash, Pruritus, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 2320 | 26709040 |
US |
22 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2321 | 26709047 |
US |
66 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2322 | 26709126 |
US |
26 | 1 |
Stress, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2323 | 26709204 |
US |
14 | 2 |
Dermatitis atopic, Weight increased, Pruritus, Incorrect dose administered, |
||||
DUPILUMAB, |
||||
| 2324 | 26709260 |
US |
2 | |
Dermatitis atopic, Dry skin, |
||||
DUPILUMAB, CETIRIZINE HCL, CETIRIZINE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, CETIRIZINE HCL, CETIRIZINE, |
||||
| 2325 | 26709269 |
US |
1 | |
Dermatitis atopic, Therapeutic response decreased, |
||||
DUPILUMAB, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, ERGOCALCIFEROL, |
||||
| 2326 | 26709420 |
US |
10 | 2 |
Sleep disorder, Dermatitis atopic, Therapeutic response shortened, Device use issue, |
||||
DUPILUMAB, BETAMETHASONE DIPROPIONATE, CRISABOROLE, |
||||
| 2327 | 26709437 |
US |
1 | |
Hyperhidrosis, Dermatitis atopic, Therapeutic response decreased, |
||||
DUPILUMAB, CETIRIZINE HCL, CETIRIZINE, FLUTICASONE PROPIONATE, ROSUVASTATIN CALCIUM, TOFACITINIB, |
||||
| 2328 | 26709598 |
US |
30 | 1 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 2329 | 26709666 |
US |
1 | |
Injection site discomfort, Dermatitis atopic, Therapeutic response decreased, Incorrect product administration duration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2330 | 26711090 |
US |
49 | 1 |
Dermatitis atopic, |
||||
LEBRIKIZUMAB-LBKZ, |
||||
| 2331 | 26703396 |
US |
1 | |
Blood pressure increased, Rash macular, Back pain, Dermatitis atopic, Rash, Pruritus, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 2332 | 26696423 |
US |
66 | 1 |
Sepsis, Dermatitis atopic, Skin ulcer, Pruritus, Skin discharge, |
||||
DUPILUMAB, |
||||
| 2333 | 26696615 |
US |
52 | 2 |
Dermatitis atopic, Loss of therapeutic response, |
||||
TRALOKINUMAB-LDRM, |
||||
| 2334 | 26696622 |
US |
||
Muscle rupture, Cutaneous lupus erythematosus, Dermatitis atopic, Product dose omission issue, |
||||
| 2335 | 26697005 |
EU |
14 | |
Dermatitis exfoliative generalised, Dermatitis atopic, |
||||
NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, MYCOPHENOLIC ACID, MYCOPHENILIC ACID, |
||||
| 2336 | 26698716 |
US |
61 | 2 |
Autoimmune disorder, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2337 | 26699984 |
US |
57 | |
Dermatitis atopic, Product dose omission issue, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 2338 | 26701082 |
US |
18 | 2 |
Dermatitis atopic, Skin haemorrhage, Condition aggravated, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 2339 | 26702134 |
17 | 1 | |
Therapy non-responder, Rash, Dermatitis atopic, Therapeutic product effect decreased, |
||||
TRALOKINUMAB-LDRM, SERTRALINE, DOXEPIN, DOXEPIN HYDROCHLORIDE, |
||||
| 2340 | 26689345 |
US |
65 | 1 |
Gastric ulcer haemorrhage, Dermatitis atopic, Impaired healing, |
||||
UPADACITINIB, |
||||
| 2341 | 26690351 |
US |
64 | 2 |
Dermatitis atopic, Erythema, Skin haemorrhage, |
||||
DUPILUMAB, |
||||
| 2342 | 26690356 |
US |
6 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2343 | 26690403 |
US |
1 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2344 | 26690411 |
US |
69 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2345 | 26690414 |
US |
22 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2346 | 26690498 |
US |
15 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 2347 | 26690500 |
US |
25 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2348 | 26690545 |
US |
2 | |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 2349 | 26690548 |
US |
61 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2350 | 26690578 |
US |
36 | 2 |
Skin swelling, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2351 | 26690647 |
US |
27 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2352 | 26690652 |
US |
35 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2353 | 26690787 |
US |
2 | |
Rash, Discomfort, Dry skin, Sleep disorder due to a general medical condition, Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, GUANFACINE, GUANFACINE HYDROCHLORIDE, GAUNFACINE, NALTREXONE, DESVENLAFAXINE SUCCINATE, |
||||
| 2354 | 26690791 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2355 | 26690860 |
US |
47 | 1 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 2356 | 26690938 |
US |
1 | |
Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, ALLOPURINOL, AMLODIPINE, ROSUVASTATIN, |
||||
| 2357 | 26690964 |
US |
5 | 1 |
Dermatitis atopic, Sleep disorder due to a general medical condition, |
||||
DUPILUMAB, |
||||
| 2358 | 26690970 |
US |
2 | |
Rash, Dermatitis atopic, Discomfort, Product dose omission issue, |
||||
DUPILUMAB, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ALBUTEROL SULFATE, ALBUTEROL, GALCANEZUMAB-GNLM, FLUTICASONE PROPIONATE, ESCITALOPRAM, RUXOLITINIB, RIZATRIPTAN, |
||||
| 2359 | 26690983 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2360 | 26691035 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, Rash, Discomfort, Sleep disorder due to a general medical condition, |
||||
DUPILUMAB, |
||||
| 2361 | 26691081 |
US |
2 | |
Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 2362 | 26691082 |
US |
16 | 1 |
Dermatitis atopic, Dermatitis, |
||||
DUPILUMAB, |
||||
| 2363 | 26691107 |
US |
2 | |
Dermatitis atopic, Intentional dose omission, |
||||
DUPILUMAB, |
||||
| 2364 | 26691194 |
US |
2 | |
Dermatitis atopic, Pruritus, Skin ulcer, Product dose omission issue, |
||||
DUPILUMAB, ORAL SEMAGLUTIDE, |
||||
| 2365 | 26691202 |
US |
1 | |
Flatulence, Diarrhoea, Hyperaesthesia teeth, Dermatitis atopic, Pain of skin, Skin fissures, |
||||
DUPILUMAB, IBUPROFEN SODIUM, IBUPROFEN, IBUPROFEN TABLETS, COATED, LORATADINE, LORATADINE TABLET, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, HYDROCORTISONE CREAM 1/2%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, PREDNISONE, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, CETIRIZINE HYDROCHLORIDE, |
||||
| 2366 | 26691204 |
US |
2 | |
Eczema, Rash, Blister, Skin fissures, Dermatitis atopic, Injection site pain, Product dose omission issue, Drug ineffective, |
||||
DUPILUMAB, LEBRIKIZUMAB-LBKZ, SERTRALINE HYDROCHLORIDE, PREDNISONE, ALPRAZOLAM, BUPROPION HYDROCHLORIDE, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, |
||||
| 2367 | 26691228 |
US |
10 | 1 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2368 | 26691276 |
US |
54 | 2 |
Ocular hyperaemia, Eye pruritus, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2369 | 26691286 |
US |
36 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2370 | 26691287 |
US |
1 | 1 |
Dermatitis atopic, Rash, Swelling face, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, CETIRIZINE HYDROCHLORIDE, |
||||
| 2371 | 26691334 |
US |
25 | 2 |
Mast cell activation syndrome, Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2372 | 26691337 |
US |
2 | |
Dermatitis atopic, Therapeutic response shortened, Product prescribing issue, |
||||
DUPILUMAB, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 2373 | 26691349 |
US |
1 | 1 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 2374 | 26691351 |
US |
1 | |
Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2375 | 26691404 |
US |
1 | |
Dermatitis atopic, Haemorrhage, Pain, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2376 | 26691527 |
US |
61 | 2 |
Dermatitis atopic, Rash, Incorrect dose administered, |
||||
DUPILUMAB, |
||||
| 2377 | 26691542 |
US |
1 | |
Dermatitis atopic, Rash, Drug ineffective, Pruritus, |
||||
DUPILUMAB, NEMOLIZUMAB-ILTO, VALSARTAN, VALSARTAN ORAL, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, |
||||
| 2378 | 26691563 |
US |
36 | 1 |
Dermatitis atopic, Pruritus, Rash macular, Rash, Eczema, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, FEXOFENADINE HYDROCHLORIDE, |
||||
| 2379 | 26691589 |
US |
20 | 2 |
Swelling face, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2380 | 26691594 |
US |
6 | 2 |
Mood disorder due to a general medical condition, Skin plaque, Dermatitis atopic, Pruritus, Eczema, Rash, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2381 | 26691639 |
US |
61 | 2 |
Dermatitis atopic, Influenza, |
||||
TRALOKINUMAB-LDRM, |
||||
| 2382 | 26691646 |
US |
17 | 1 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 2383 | 26691658 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2384 | 26691669 |
US |
2 | |
Skin exfoliation, Dermatitis atopic, Pruritus, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2385 | 26691671 |
US |
2 | 2 |
Dermatitis atopic, Illness, |
||||
DUPILUMAB, |
||||
| 2386 | 26691676 |
US |
1 | |
Dermatitis atopic, Neurodermatitis, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2387 | 26691690 |
US |
39 | 2 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2388 | 26691691 |
US |
2 | |
Dermatitis atopic, Neurodermatitis, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, OMALIZUMAB, |
||||
| 2389 | 26691692 |
US |
70 | 2 |
Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2390 | 26691752 |
US |
32 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2391 | 26691760 |
US |
20 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2392 | 26691768 |
US |
47 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2393 | 26691877 |
US |
36 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2394 | 26691881 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2395 | 26691882 |
US |
17 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2396 | 26691885 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2397 | 26691888 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2398 | 26691890 |
US |
56 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2399 | 26691892 |
US |
35 | 1 |
Dermatitis atopic, Pruritus, Dry skin, Erythema, Skin exfoliation, Sleep disorder due to a general medical condition, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2400 | 26691894 |
US |
17 | 2 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30